SynthesisBMC cancer2026
The efficacy and safety of neoadjuvant chemotherapy plus immune check point inhibitors for locally advanced cervical cancer: a systematic review and meta-analysis.
Synthesis in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveImmune checkpoint inhibitors (ICIs) enable organ preservation strategies and surgical de-escalation in multiple cancers.In locally advanced cervical cancer (LACC), neoadjuvant chemotherapy plus immune checkpoint inhibitors (NACI) may improve tumor response.This study conducted a systematic review and meta-analysis to evaluate the response rates and safety of NACI in LACC.
methodsWe systematically searched PubMed, Web of Science, Cochrane Library, and Embase from inception to March 2025, including major congress abstracts. Phase II/III trials or retrospective analyses reporting pathological complete response (pCR), objective response rate (ORR), and adverse events (AEs) for NACI in LACC were included. Two investigators independently extracted data. Pooled rates were calculated using STATA 18.0 with random-effects models (I² statistic assessed heterogeneity).
resultsThree clinical studies involving 162 patients with locally advanced cervical cancer were included in the meta-analysis. The pooled ORR was 95.5% (95% confidence interval [CI],90.8-98.6%), while the pooled pCR rate was 45.5% (95% CI, 27.7-63.2%). Grade 3 or higher AEs occurred at a pooled rate of 35.5% (95% CI, 28.2-42.9%). Sensitivity analysis confirmed the reliability of the meta-analytic findings.
conclusionThe combination of chemotherapy and PD-1/PD-L1 inhibitors achieved 45.5% pCR and tolerable toxicity .The results provide theoretical basis for further studies in reducing the scope of surgery under specific conditions to minimize complicationsr surgery or preserving fertility. SYNOPSIS: Neoadjuvant PD-1/PD-L1 inhibitors with chemotherapy achieved 95.5% ORR and 45.5% pCR in LACC (3 studies, n=162). Grade ≥3 AEs occurred in 35.5% of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.